Search Results

You are looking at 1 - 6 of 6 items for :

  • pharmacokinetics x
  • Laboratory Medicine x
Clear All
Open access

Yuchi Jia

, phosphonomycin amino butyl alcohol three salt granules, and fosfomycin two sodium salt for injection. Although the clinical application of phosphomycin has increased in recent years, there are few clinical reports in China. According to the related literatures at home and abroad, this review briefly introduces fosfomycin in the following three aspects: progress in synthetic methods, pharmacokinetic and pharmacodynamic characteristics, and antibacterial activities, to provide references for clinical rational use. 2 The synthesis of fosfomycin Fosfomycin was first

Open access

Zhi-liang Hu, Hong-xia Wei, Wen-hu Yao and Yong-feng Yang

. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother 2007;60:162-165. 4 Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005;43: 2163-2167. 5 Liu P, Foster G, LaBadie RR, Gutierrez MJ, Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008;48:73-84. 6

Open access

Yue Sun, Ying Liu and Hongming Zhu

therapy for chronic osteomyelitis in adults. Clin Infect Dis, 2012, 54(3): 393-407. 6 Conterno LO, Turchi MD. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev, 2013, 9(19): 1292. 7 Tone A, Nguyen S, Devemy F, et al . Six-week versus twelve – week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care, 2015, 38(2): 302-307. 8 Landersdorfer CB, Bulitta JB, Kinzig M, et al . Penetration of antibacterials into bone pharmacokinetic

Open access

Consensus. Chinese Consensus on Combination Therapy of Chronic Hepatitis B

Professional Staff Committee of Combination Therapy of Chronic Hepatitis B

Jun Cheng

AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323. 25 Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-551. 26 Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695. 27 Sarin SK

Open access

Bo Li

. Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. Virol Sin, 2013,28(3): 167-173. 10 Metzger DW. Interleukin-12 as an adjuvant for induction of protective antibody responses. Cytokine, 2010, 52(1-2):102-107. 11 Wei F, Wang H, Zhang J, et al . Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12. J Exp Clin Cancer Res, 2013,32:5. 12 Saghafian-Hedengren S, Sohlberg E, Theorell J, et al . Epstein-Barr virus coinfection in children boosts

Open access

Guoxiu Lu

, and other factors of the current, local, hospital, department, and use empirical antimicrobial agents early [ 24 ]. Moreover, whether the case is hospital-acquired or out-of-hospital infection should be determined, and the presence of a clear focus of infection should be known. The selected drug should be a wide spectrum of antimicrobial agent that covers possible pathogenic microorganisms (bacterial or fungal) and has good penetration in the likely infected tissue. The pharmacokinetics of the antimicrobials will change significantly during the course of treatment